Physician profile
Avid J Muniz
NPI 1417919804
$5,252.82
in general payments reported to CMS, 2019-2025
27 companies · $1,023 in 2025
The $1,023 reported for 2025 was more than what 78% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $580 · 2020: $319 · 2021: $491 · 2022: $789 · 2023: $1,165 · 2024: $887 · 2025: $1,023.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,046 · Education: $28.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,045.58 |
| Education | $28.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,083.53 | 2019-2025 | Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $594.51 | 2021-2025 | |
| Bayer Puerto Rico INC. | $566.92 | 2023-2025 | Kerendia |
| E.R. Squibb & Sons, L.L.C. | $351.05 | 2021-2024 | Eliquis |
| Boston Scientific Corporation | $256.69 | 2021-2025 | Avvigo Guidance System, Greenlight Xps |
| Boehringer Ingelheim Pharmaceuticals, INC. | $247.06 | 2021-2025 | Jardiance |
| Novo Nordisk INC | $183.65 | 2023-2025 | Ozempic |
| Mallinckrodt Hospital Products INC. | $181.18 | 2020-2025 | Acthar, Terlivaz |
| Amgen INC. | $162.75 | 2019-2025 | Tavneos, Krystexxa |
| Glaxosmithkline, LLC. | $156.79 | 2024-2025 | Benlysta |
| Janssen Pharmaceuticals, INC | $144.94 | 2020-2022 | |
| Alexion Pharmaceuticals, INC. | $144.34 | 2023 | |
| Vifor Pharma, INC. | $143.76 | 2024-2025 | Veltassa |
| Otsuka America Pharmaceutical, INC. | $125.00 | 2023 | Jynarque |
| Genzyme Corporation | $118.21 | 2022-2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $115.59 | 2019 | |
| Medtronic, INC. | $114.70 | 2023 | Micra |
| Sanofi-Aventis U.S. LLC | $100.00 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $87.59 | 2019 | |
| Calliditas Therapeutics US INC. | $82.44 | 2023-2024 | Tarpeyo |
| Bard Peripheral Vascular, INC. | $81.62 | 2022 | |
| Abbott Laboratories | $58.94 | 2019 | |
| Ani Pharmaceuticals, INC. | $45.84 | 2025 | Purified Cortrophin Gel |
| Travere Therapeutics, INC. | $33.16 | 2023 | |
| Kyowa Kirin, INC. | $29.81 | 2024 | Crysvita |
| Takeda Pharmaceuticals U.S.A., INC. | $22.75 | 2019 | |
| Pbg Puerto Rico LLC | $20.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avid Muniz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.